Selected Publications in Peer-Reviewed Journals

• Gill, A.L., Premasiri, A.S., Vieira, F.G. Type I PRMT Inhibition Protects Against C9ORF72 Arginine-Rich Dipeptide Repeat Toxicity Frontiers in Pharmacology (2020)
• Gill, A.L., Wang, M.Z., Levine, B., Premasiri, A., Vieira, F.G. Primary Neurons and Differentiated NSC-34 Cells Are More Susceptible to Arginine-Rich ALS Dipeptide Repeat Protein-Associated Toxicity than Non-Differentiated NSC-34 and CHO Cells International Journal of Molecular Sciences (2019)
• Gill, C., Phelan, J.P., Hatzipetros, T., Kidd, J.D., Tassinari, V.R., Levine, B., Wang, M.Z., Moreno, A., Thompson, K., Maier, M., Grimm, J., Gill, A., Vieira, F.G. SOD1-positive aggregate accumulation in the CNS predicts slower disease progression and increased longevity in a mutant SOD1 mouse model of ALS. Scientific Reports (2019)
• Tassinari, V. R. and Vieira, F. G. A High-throughput qPCR-based Method to Genotype the SOD1G93A Mouse Model for Relative Copy Number. Bio-protocol. 2019 9(12): e3276. DOI: 10.21769/BioProtoc.3276.
• Maier, M., Welt, T., Wirth, F., Montrasia, F., Preisig, D., McAfoose, J., Vieira, F.G., Kulic, L., Spani, C., Strehle, T., Perrin, S., Weber, M., Hock, C., Nitsch, R.M., Grimm, J. A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis. Science Translational Medicine (2018)
• Vaughan S.K., Sutherland, N.M., Zhang, S., Hatzipetros, T., Vieira, F., Valdez, G. The ALS-inducing factos, TDP43-A315T and SOD1-G93A, directly affect and sensitize sensory neurons to stress. Scientific Reports (2018)
• Vieira, F.G., Hatzipetros, T., Thompson, K., Moreno, A.J., Kidd, J.D., Tassinari, V.R., Levine, B., Perrin, S., Gill, A. CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits. IBRO Reports (2017). doi: 10.1016/j.ibror.2017.03.001.
• Berry, J.D., Paganoni, S., Atassi, N., Macklin, E.A., Goyal, N., Rivner, M., Simpson, E., Appel, S., Grasso, D.L., Mejia, N.I., Mateen, F., Gill, A., Vieira, F.G., Tassinari, V.R., Perrin, S. Phase IIA Trial of Fingolimod for ALS Demonstrates Acceptable Acute Safety and Tolerability. Muscle & Nerve (2017)
• Theo Hatzipetros, Joshua D Kidd, Andy J Moreno, Kenneth Thompson, Alan Gill and Fernando G. Vieira. A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS. JOVE. in-press. 2015
• Vaughan S.K., Kemp, Z., Hatzipetros, T., Vieira, F., Valdez, G. Degeneration of proprioceptive sensory nerve endings in mice harboring amyotrophic lateral sclerosis-causing mutations. Journal of Comparative Neurology (2015)
• Steve Perrin. Preclinical research: Make mouse studies work. Nature. 2014 Mar 27;507(7493):423-5.
• Fernando G. Vieira*, Eva Ladow*, Andy Moreno, Joshua D. Kidd, Beth Levine, Kenneth Thompson, Alan Gill, Steven Finkbeiner, Steven Perrin. Dexpramipexole is ineffective in two models of ALS related neurodegeneration. PlosOne 2014 doi: 10.1371/journal.pone.0091608. eCollection 2014. (*these authors contributed equally to this work)
• Theo Hatzipetros, Laurent P. Bogdanik, Valerie R. Tassinari, Joshua D. Kidd, Andy Moreno, Crystal Davis, Melissa Osborne, Andrew Austin, Fernando G. Vieira, Cathleen Lutz, Steve Perrin. C57BL/6J congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus of the colon without exhibiting key features of ALS. Brain Res. 2013, ISSN 0006-8993 doi: 10.1016/j.brainres.2013.10.013. Epub 2013 Oct 18.
• Dong Liu, Chaoxu Liu, Jungiang Li, Kazem Azadoi, Yun Yang, Zhou Fei, Kefeng Dou, Neil W. Kowall, Han-Pil Choi, Fernando G. Vieira, Jing-Hua Yang. Proteomic analysis reveals differentially regulated protein acetylation in human amyotrophic lateral sclerosis spinal cord. PlosOne, 2013, 8(12): e80779. doi: 10.1371/journal.pone.0080779
• Boxer AL, Gold M, Huey E, Hu WT, Rosen H, Kramer J, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, Van Kammen D, Cantillon M, Zahs K, Jackson G, Salloway S, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian ZS, Sutherland M, Abushakra S, Lewcock J, Farese R, Kenet RO, Laferla F, Perrin S, Whitaker S, Honig L, Mesulam MM, Boeve B, Grossman M, Miller BL, Cummings JL. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement. 2013 Mar;9(2):189-98. doi: 10.1016/j.jalz.2012.03.003. Epub 2012 Oct 10.
• Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT 3rd, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012 Oct 11;490(7419):187-91. doi: 10.1038/nature11556.
• John M. Lincecum*, Fernando G. Vieira*, Monica Z. Wang, Kenneth Thompson, Gerald S. DeZutter, Joshua Kidd, Andy Moreno, Ricardo Sanchez, Isa J. Carrion, Beth A. Levine, Bashar M. Al-Nakhala, Shawn M. Sullivan, Alan Gill, Steve Perrin. From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis. Nat Genet. 2010 May;42(5):392-9. doi: 10.1038/ng.557. Epub 2010 Mar 28. (*these authors contributed equally to this work)
• Albert C. Ludolph, Caterina Bendotti, Eran Blaugrund, Adriano Chio, Linda Greensmith, Jean-Philippe Loeffler, Richard Mead, Heiko G. Niessen, Susanne Petri, Pierre-Francois Pradat, Wim Robberecht, Markus Ruegg, Birgit Schwalenstöcker, Detlev Stiller, Leonard van den Berg, Fernando Vieira, Stephan von Horsten. Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph Lateral Scler. 2010;11(1-2):38-45. doi: 10.3109/17482960903545334.
• Alan Gill, Joshua Kidd, Fernando Vieira, Kenneth Thompson, Steve Perrin. >No benefit from chronic lithium dosing in a sibling-matched, gender balanced, investigator-blinded trial using a standard model of familial ALS. PlosOne. 2009 Aug 3;4(8):e6489. doi: 10.1371/journal.pone.0006489.
• Sean Scott, Janice E. Kranz, Jeff Cole, John M. Lincecum, Kenneth Thompson, Nancy Kelly, Alan Bostrom, Jill Theodoss, Bashar M. Al-Nakhala, Fernando G. Vieira, Jeyanthi Ramasubbu, James A. Heywood. Design, power and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler. 2008;9(1):4-15. doi: 10.1080/17482960701856300
• Clark JC, Brennan A, Ramesh TM, Heywood JA. Novel trends in orphan market drug discovery: amyotrophic lateral sclerosis as a case study. Front Biosci. 2002 Aug 1;7:c83-96.
• Janson CG, Ramesh Tm, During MJ, Leone P, Heywood J. Human intrathecal transplantation of peripheral blood stem cells in amyotrophic lateral sclerosis. J. Hematother Stem Cell Res. 2001 Dec;10(6);913-5.